Assessing Inflammation in Psoriasis Patients Using Advanced PET Scanning and Diet Changes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of the new EXPLORER PET scanner technology in measuring systemic and cutaneous inflammation in psoriasis patients. Participants will follow a nutritionally balanced diet for six weeks, transitioning from a typical Western diet, to determine if this dietary change leads to a reduction in inflammation detectable by the EXPLORER PET scan. The study aims to correlate dietary patterns with inflammation levels, potentially providing insights into dietary interventions for managing psoriasis. The research will involve both imaging and dietary assessments to gather comprehensive data on the participants' health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (\>18 year)
* Both sexes
* Must have a history of psoriasis of at least 3% body surface area affected by skin psoriasis (in a body area that the subject will allow the PI to perform several skin biopsies as noted below (optional)) and may carry a diagnosis of psoriatic arthritis as well
* Patients will have a BMI of \>/=25 which is consistent with being overweight - Willing and able to fast for at least 6 hours before and for the duration of the scan visit
* No strenuous exercise for 24 hours prior to being scanned
* Recruited patients must habitually consume a WD-type diet that will be evaluated by using DHQ III food frequency questionnaire along with three-day food record14. Subsequently, the Healthy Eating Index will be calculated and participants with a poor dietary pattern (score below 58) will be eligible for the study15.

Exclusion Criteria:

* Those taking anti-diabetic oral or injected medications
* Those already ingesting a caloric- or component-restricted diet
* Vegan, vegetarian or food allergy or intolerance to the ingredients of the diet
* \>5% change in body weight in the last 2 months
* Those taking systemic medications for the purpose of treating psoriasis or psoriatic arthritis for at least 3 months prior to first PET scan or during the duration of the trial
* Self-reported history of dysphoria or anxiety in closed spaces (claustrophobia)
* Uncontrolled diabetes or blood glucose level greater than 180 mg/dl at the time of radiotracer injection
* Body weight \>240 kg due to limitations of the scanner bed
* Known inflammatory or other infectious disease that can confound assessment
* Pregnant or breast-feeding (urine pregnancy test will be administered prior to start of each PET/CT session for all participants who are able to get pregnant between 18 to 60 years old, unless documented hysterectomy or bilateral ovarian removal is available, because of risks from ionizing radiation)
* Inability to lie motionless on the scanner bed with the arms by the side for up to 60 minutes
* Currently participating in another conflicting research study. Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.
* Unwilling to sign informed consent
* Inability to understand the risks and benefits of the study
* Prisoners

Where it's running

• University of California, Davis - Dermatology Department
  Sacramento, California, United States Recruiting

Study contacts

• Principal investigator: Samuel T Hwang, MD, PhD — UC Davis SOM Department of Dermatology
• Study coordinator: Salsala Nasim, BS
• Email: sanasim@ucdavis.edu
• Phone: 9165512636

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Is XJH05 Ointment Effective for Plaque Psoriasis?

  This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07780929

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

• SHR-1139 injectable treatment for adults with plaque psoriasis

  This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangzhou · NCT07719530

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.